Cinda Biotech announced that in the first half of 2026, the company's product revenue recorded over RMB 8.2 billion, an increase of more than 55%; of these, product revenue for the second quarter exceeded RMB 4.3 billion, an increase of about 60% over the previous year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.